HEDS is part of the School of Health and Related Research (ScHARR) at the University of Sheffield. We undertake research, teaching, training and consultancy on all aspects of health related decision science, with a particular emphasis on health economics, HTA and evidence synthesis.

Monday, 5 December 2016

European Commission public consultation on strengthening EU cooperation on HTA

“This public consultation aims to gather detailed views and opinions relating to the future of the EU cooperation on HTA, as proposed in the Inception Impact Assessment published by the European Commission (see Reference documents). The results of this public consultation will feed into the impact assessment process which the Commission services are currently preparing on strengthening EU cooperation on HTA.”

Image: European Flag: Rock Cohen

The consultation closes on 13th January 2017.  Further details are available here.

Friday, 2 December 2016

New Edition of Measuring and Valuing Health Benefits for Economic Evaluation released

The second edition of the highly popular Measuring and Valuing Health Benefits for Economic Evaluation has been published.
Image of book cover
Measuring and
 Valuing Health Benefits
for Economic Evaluation
Written by HEDS colleagues Professor John Brazier, Professor Julie Ratcliffe (Flinders Health Economics Group), Professor Aki Tsuchiya and Professor Joshua Salomon from the Harvard School of Public Health.,

  • The book addresses all relevant theoretical and practical considerations in the measurement and valuation of health benefits. It contains practical applications to help clarify understanding and make relevant links to the real world, and includes a glossary of key terms to aid understanding of common terms used by practitioners.
Measuring and Valuing Health Benefits for Economic Evaluation examines the measurement and valuation of health benefits, reviews the explosion of theoretical and empirical work in the field, and explores an area of research that continues to be a major source of debate. It addresses the key questions in the field including the definition of health, the techniques of valuation, and the problem of choosing the right instrument. This is an ideal resource for anyone wishing to gain a specialised understanding of health benefit measurement in economic evaluation, especially those working in the fields of health economics, public sector economics, pharmacoeconomics and health services research.
  • Measuring and Valuing Health Benefits for Economic
    examines the measurement and
    valuation of health benefits, reviews the
    explosion of theoretical and empirical work in
    the field, and explores an area of research that
    continues to be a major source of debate. It
    addresses the key questions in the field including
    the definition of health, the techniques of
    valuation, and the problem of choosing the
    right instrument.
    This is an ideal resource for anyone wishing to
    gain a specialised understanding of health benefit
    measurement in economic evaluation, especially
    those working in the fields of health economics,
New to this Edition:
  • Covers all new measures of health and wellbeing for example ICECAP, ASCOT and numerous condition-specific measures and revisions to existing widely used ( measures for example 5 level version of EQ-5D, DF-6D V2 and AQoL-2.

NICE approves three quarters of CDF group 1 drugs for routine use

From the NICE website:
“More than 75% of treatments in the Cancer Drugs Fund (CDF) which have been looked at again by NICE have received positive recommendations for routine NHS use.

It means that drugs, which patients previously had to apply to the CDF for, will now be available routinely on the NHS.  NICE is currently reappraising 11 drug indications in the first group of the CDF, and of the nine looked at so far, seven have been approved at draft or final guidance stage. None have yet been rejected in final guidance, with the remaining two currently in the process.”

Image: NICE by Sasha Cresdee

Thursday, 1 December 2016

Latest Publications from HEDS in November

Here are the latest publications from November, including those 'In Press' by HEDS colleagues and their collaborators. 

Cooper KL, Martyn-StJames M, Kaltenthaler E, Dickinson K, Cantrell A, Ren S, et al. Complementary and alternative medicine for management of premature ejaculation: a systematic review and meta-analysis. Sex Med.

Image of PharmacoEconomics Journal
© PharmacoEconomics
Carroll C, Tappenden P, Rafia R, Hamilton J, Chambers D, Clowes M, et al. Evolocumab for Treating Primary Hypercholesterolaemia and Mixed Dyslipidaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics.

Kuczawski ML, Stevenson M, Goodacre S, Teare MD, Ramlakhan S, Morris F, et al. Should all anticoagulated patients with head injury receive a CT scan? Decision-analysis modelling of an observational cohort. BMJ Open.

Stevenson MD, wailoo, hernandez, gray, stevens, archer, et al. The cost-effectiveness of sequences of biological disease-modifying antirheumatic drug treatment within England for patients with rheumatoid arthritis who can tolerate methotrexate. J Rheumatol. Journal of Rheumatology.

McNamee P, Murray E, Kelly MP, Bojke L, Chilcott J, Fischer A, et al. Designing and Undertaking a Health Economics Study of Digital Health Interventions. Am J Prev Med. 2016 Nov;51(5):852–60.
Image of American Journal of  Preventive Medicine
© American Journal of
Preventive Medicine

Kaltenthaler E, Carroll C, Hill-McManus D, Scope A, Holmes M, Rice S, et al. Issues Related to the Frequency of Exploratory Analyses by Evidence Review Groups in the NICE Single Technology Appraisal Process. PharmacoEconomics - Open. 2016 Nov 4;

Lorgelly PK, Doble B, Rowen D, Brazier J, investigators C 2015. Condition-specific or generic preference-based measures in oncology? A comparison of the EORTC-8D and the EQ-5D-3L. Qual Life Res [Internet]. Netherlands; 2016 Nov 9; Available from: http://www.ncbi.nlm.nih.gov/pubmed/27830513

Mulhern B, Norman R, Lorgelly P, Lancsar E, Ratcliffe J, Brazier J, et al. Is Dimension Order Important when Valuing Health States Using Discrete Choice Experiments Including Duration? Pharmacoeconomics [Internet]. New Zealand; 2016 Nov 21; Available from: http://www.ncbi.nlm.nih.gov/pubmed/27873226

Image of Health and Quality of Life Outcomes
© Health and Quality of
Life Outcomes
Tong T, Thokala P, McMillan B, Ghosh R, Brazier J. Cost effectiveness of using cognitive screening tests for detecting dementia and mild cognitive impairment in primary care. Int J Geriatr Psychiatry [Internet]. England; 2016 Nov 22; Available from: http://www.ncbi.nlm.nih.gov/pubmed/27874210

Poku E, Duncan R, Keetharuth A, Essat M, Phillips P, Woods HB, et al. Patient-reported outcome measures in patients with peripheral arterial disease: a systematic review of psychometric properties. Heal Qual Life Outcomes [Internet]. England; 2016 Nov 24;14(1):161. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27881127

Wednesday, 30 November 2016

Cochrane Collaboration Issue 11, 2016…

….is complete.  The website lists protocols and methodology papers as well, but we’ll just flag up the notable reviews; these being……
  • Interferons‐beta versus glatiramer acetate for relapsing‐remitting multiple sclerosis
  • Adjuvant platinum‐based chemotherapy for early stage cervical cancer
  • Gene therapy for sickle cell disease
  • Inhaled corticosteroids with combination inhaled long‐acting beta2‐agonists and long‐acting muscarinic antagonists for chronic obstructive pulmonary disease
  • Cell‐based therapies for amyotrophic lateral sclerosis/motor neuron disease
  • Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease‐modifying anti‐rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta‐analysis (NMA)

Monday, 28 November 2016

Immuno-oncology Drug Development Workshop

Nick Latimer was invited to give a talk at the FDA/AACR Immuno-oncology Drug Development Workshop held in Washington, DC in October. The aim of the workshop was to develop a path forward for evaluating an immuno-oncology-focused nonclinical and clinical development paradigm, including a re-definition of biological outcome measures and clinical endpoints, leading to innovative clinical trial designs and statistical methods in the development of immuno-oncology clinical trials.

There were some extremely interesting talks on outcome definitions, with the FDAs own research leading the way in addressing issues with the definition of disease progression. Nick gave a talk on methods for analysing survival data in the absence of proportional hazards - something which is not uncommon in technology appraisals undertaken in the UK. Transcripts and slides from the workshop are available here.

Image: Washington DC by BKL

Friday, 25 November 2016


BBC Radio 6 Music's 'Wear Your Old Band T-Shirt To Work Day' returns for its ninth year.  HEDS joined in again….well 11 of us :)

The usual suspects…….2015’s post.

Global Health Cost Effectiveness Analysis (GHCEA) Registry

The Registry has just been launched and is the first comprehensive database to compile articles utilizing the “cost per DALY averted” metric to measure the efficacy of health interventions.  The methods used to populate the database look good, as does the website.  Whether a cost per DALY averted is useful for resource allocation decisions, is a different matter completely….

Thursday, 24 November 2016

Advanced Simulation Methods Short Course


Within healthcare decision making, cohort Markov models and decision trees are frequently used. However, in some situations these are not the most appropriate modelling methods. This course provides an in-depth review of individual-level simulation rationale, techniques and methodologies with a particular focus on discrete event simulation and its practical application to inform healthcare decision making. From the fundamentals of a basic model the course will progress to modelling complex systems, verification and interpreting output, as well as exploring alternative software options.

What does the course deliver?

This course aims to provide participants with the skills required to be able to undertake simulation projects to a professional level. It will be both theoretically-based and practically-based, with the use of the Simul8 software package. It will cover the use of discrete-event simulation to assess the impact of alternative options within a local system with resource constraints and the use of patient-level simulation for health economic modelling.

Who will benefit from this course?

This course is primarily for health economic modellers who want to broaden their skill base, as well as healthcare decision makers who would like to understand more about patient-level simulation and when it might be useful. Participants must have a basic level of knowledge of health economic modelling in order to follow the course.

Course content

The course will consist of a mixture of presentations and practical use of Simul8, both following the lecturer and within individual exercises.

The course runs from Tuesday 24th - Thursday 26th January 2017, in Sheffield.  Further details are available here.

Book now for an early bird discount!

Image: Learn by Voluntary Amputation

Tuesday, 22 November 2016

Fully-funded PhD studentships in Public Health, Health Economics and Decision Science

Generously funded by the Wellcome Trust, our four-year PhD Programme in Public Health Decision Science provides unique interdisciplinary training to equip graduates to be public health leaders and decision scientists of the future.

The first year offers a unique training opportunity; students will have access to senior scientists and public health decision makers and take a range of self-selected taught modules to complement their existing skills. Health and social sciences graduates will develop advanced quantitative analytical skills and those with quantitative analytical degrees will receive training in public health. Rotations through three “research attachments” will allow students to experience research in multiple topic areas with potential supervisors before finalising the topic of the research project they will complete during years two to four.

We award 5 studentships per year (three funded by the Wellcome Trust and two by the University of Sheffield), two of which can cover overseas fees.
Image: PhD by asheshwor

The closing date for receipt of all required documentation and references is 16 December 2016.  More information & how to apply can be found here.